<DOC>
	<DOC>NCT00404612</DOC>
	<brief_summary>The objective of this study is to evaluate the safety and efficacy of LX211 as therapy in subjects with active non-infectious uveitis</brief_summary>
	<brief_title>A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis</brief_title>
	<detailed_description />
	<mesh_term>Uveitis</mesh_term>
	<mesh_term>Panuveitis</mesh_term>
	<mesh_term>Uveitis, Posterior</mesh_term>
	<mesh_term>Uveitis, Intermediate</mesh_term>
	<mesh_term>Pars Planitis</mesh_term>
	<criteria>Documented history of noninfectious intermediate, anterior and intermediate, posterior or panuveitis uveitis Current uveitis therapy must conform to one of the following: 1. Prednisone monotherapy at a dose of ≥ 10 mg/day (or equivalent) for ≥ 2 weeks prior to randomization 2. Have received ≥ 2 injections of corticosteroid (intravitreal or periocular) for control of disease within the past 8 months, but not within 2 weeks of randomization; subjects may also be receiving systemic corticosteroid therapy 3. Receiving monotherapy with azathioprine, mycophenolate mofetil, mycophenolic acid or methotrexate for at least 2 weeks prior to randomization 4. Receiving prednisone in addition to one immunomodulatory agent from among cyclosporine, tacrolimus, azathioprine, mycophenolate mofetil, mycophenolic acid and methotrexate for at least 2 weeks prior to randomization 5. Subjects for whom corticosteroid therapy (systemic or local) is medically inappropriate or who refuse corticosteroid therapy Grade of 2+ or higher for vitreous haze at time of enrollment Considered by the investigator to require immunomodulatory therapy. Not planning to undergo elective ocular surgery during the study Uveitis of infectious etiology Clinically suspected or confirmed central nervous system or ocular lymphoma Primary diagnosis of anterior uveitis</criteria>
	<gender>All</gender>
	<minimum_age>13 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>uveitis</keyword>
	<keyword>calcineurin</keyword>
</DOC>